Menu
Recruiting NCT05805033

Peri-Implant Soft Tissue Integration in Humans: Influence of Material

No phase Interventional Healthy Subjects

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Mucointegration.
Who it may be relevant to
Registry conditions: Healthy Subjects. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Belgium
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The purpose of this study is to compare the mucointegration of 2 types of surface roughness of zirconia abutments with titanium. The surface roughness will be machined and ultra-polished.

Detailed description

After being informed about the study and potential risks, all participants give written informed consent and eligibility for study entry.

The day of the surgery, patients will be randomized in machined zirconia or ultra-polished zirconia.

After 8 weeks of healing, biopsy are separated in two groups according to the removal:

* if the abutment come together with the surrounding soft tissues, it goes for a non decalcified histology for histometric measurements to determine the dimensions of biological width (sulcus depth, epithelial and connective adhesion) * if the abutment come separate of the surrounding tissue, the soft tissue goes for immunohistochemistry to analyse pro-inflammatory cells and vascularisation and the abutment for SEM analysis to calculate the percentage of adhesion of the cells on the abutment

Interventions

  • Other Mucointegration
    Placement of abutment on a dental implant to study mucointegration

Primary outcome measures

  • Histomorphometry [Time frame: 8 weeks of healing]
  • Immunohistology [Time frame: 8 weeks of healing]

Eligibility criteria

Inclusion criteria

  • Participants have to voluntarily sign the informed consent form before any study related action
  • Patients aged 18 or over
  • Patients with one or more missing teeth in the maxillary or mandible area, seeking implant therapy
  • Men/women
  • Patients in good systemic health (ASA I/ II) and no contraindication for oral surgical interventions
  • Patients requiring a replacement of missing teeth; the tooth at the implant site(s) must have been extracted or lost at least 12 weeks before the date of implantation
  • At least 3 mm of fibrous mucosa in the bucco-lingual dimension
  • Full mouth plaque score (FMPI) lower than or equal to 25%
  • At least a diameter of 4 mm for the implant (regular diameter)

Exclusion criteria

  • Autoimmune disease requiring medical treatment
  • Medical conditions requiring prolonged use of steroids
  • Use of Bisphosphonates intravenously or more than 3 years of oral use
  • Infection (local or systemic) - patients with gingivitis or active local infection will undergo a medical treatment prior to the entrance to the study, and each individual will be evaluated for suitability; in case of a systemic infection, the evaluation will be based on medical anamneses, and if necessary, a patient will be referred to relevant medical tests
  • Current pregnancy or breastfeeding women
  • Alcoholism or chronical drug abuse
  • Immunocompromised patients
  • Uncontrolled diabetes
  • Smokers
  • Prisoners
  • Implant's diameter under 4 mm (narrow implant)
  • Conditions or circumstances, in the opinion of the investigator, which would prevent completion of the study or interference with analysis of study results, such as history of non-compliance, or unreliability

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

Belgium · 1 center
  • Clémentine Canuel — Liège

Identifiers

NCT: NCT05805033 · 2022/189 · B7072022000023

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗